Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status
This review focuses on the clinical development of the prototype broad spectrum inhibitor of cyclin-dependent kinases (CDKs), flavopiridol, now undergoing Phase II single-agent trials and Phase I combination trials (with paclitaxel and cisplatin). Preclinically, flavopiridol is a potent inhibitor of...
Uložené v:
| Vydané v: | Expert opinion on investigational drugs Ročník 9; číslo 12; s. 2903 - 2911 |
|---|---|
| Hlavný autor: | |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
England
Ashley Publications Ltd
01.12.2000
Taylor & Francis |
| Predmet: | |
| ISSN: | 1354-3784, 1744-7658 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | This review focuses on the clinical development of the prototype broad spectrum inhibitor of cyclin-dependent kinases (CDKs), flavopiridol, now undergoing Phase II single-agent trials and Phase I combination trials (with paclitaxel and cisplatin). Preclinically, flavopiridol is a potent inhibitor of CDKs 1, 2 and 4 in cell-free assays (IC50 in the region of 100 nM) and tumour cell growth in vitro (typical IC50 in the region of 100 nM). The drug showed in vivo antitumour activity (using iv., ip. or oral dosing) against a variety of human tumour xenografts, especially when administered on a regular daily, rather than weekly, schedule and most notably against prostate carcinoma, head and neck cancer, non-Hodgkin's lymphoma and leukaemia. The major toxicities observed in rodents were on the bone marrow and gastrointestinal tract. Pharmacokinetics were linear with dose and with a bi-exponential decline both in rodents and man. Oral bioavailability in rodents is in the region of 20%. Glucuronidation appears to be the major route of metabolism. Single-agent clinical trials have mainly used a 72 h continuous infusion schedule. Dose-limiting toxicities were diarrhoea and hypotension. Plasma concentrations in excess of those required for in vitro enzyme or cell growth inhibition are achievable. While there has been some evidence of single-agent antitumour activity (partial responses in a patient with renal cancer and another with gastric cancer), ongoing combination studies, especially with paclitaxel, where preclinical synergistic antitumour effects are observed, are promising. Doubt as to whether CDKs are the sole target responsible for the drug's antitumour effects have been raised by preclinical observations of apoptosis of non-cycling cells, effects on endothelial cells and non-CDK proteins, such as aldehyde dehydrogenase and glycogen phosphorylase, potent effects on PTEFb and transcription and its ability to directly interact with DNA. |
|---|---|
| AbstractList | This review focuses on the clinical development of the prototype broad spectrum inhibitor of cyclin-dependent kinases (CDKs), flavopiridol, now undergoing Phase II single-agent trials and Phase I combination trials (with paclitaxel and cisplatin). Preclinically, flavopiridol is a potent inhibitor of CDKs 1, 2 and 4 in cell-free assays (IC(50)in the region of 100 nM) and tumour cell growth in vitro (typical IC(50)in the region of 100 nM). The drug showed in vivo antitumour activity (using iv., ip. or oral dosing) against a variety of human tumour xenografts, especially when administered on a regular daily, rather than weekly, schedule and most notably against prostate carcinoma, head and neck cancer, non-Hodgkin's lymphoma and leukaemia. The major toxicities observed in rodents were on the bone marrow and gastrointestinal tract. Pharmacokinetics were linear with dose and with a bi-exponential decline both in rodents and man. Oral bioavailability in rodents is in the region of 20%. Glucuronidation appears to be the major route of metabolism. Single-agent clinical trials have mainly used a 72 h continuous infusion schedule. Dose-limiting toxicities were diarrhoea and hypotension. Plasma concentrations in excess of those required for in vitro enzyme or cell growth inhibition are achievable. While there has been some evidence of single-agent antitumour activity (partial responses in a patient with renal cancer and another with gastric cancer), ongoing combination studies, especially with paclitaxel, where preclinical synergistic antitumour effects are observed, are promising. Doubt as to whether CDKs are the sole target responsible for the drug's antitumour effects have been raised by preclinical observations of apoptosis of non-cycling cells, effects on endothelial cells and non-CDK proteins, such as aldehyde dehydrogenase and glycogen phosphorylase, potent effects on PTEFb and transcription and its ability to directly interact with DNA. This review focuses on the clinical development of the prototype broad spectrum inhibitor of cyclin-dependent kinases (CDKs), flavopiridol, now undergoing Phase II single-agent trials and Phase I combination trials (with paclitaxel and cisplatin). Preclinically, flavopiridol is a potent inhibitor of CDKs 1, 2 and 4 in cell-free assays (IC(50)in the region of 100 nM) and tumour cell growth in vitro (typical IC(50)in the region of 100 nM). The drug showed in vivo antitumour activity (using iv., ip. or oral dosing) against a variety of human tumour xenografts, especially when administered on a regular daily, rather than weekly, schedule and most notably against prostate carcinoma, head and neck cancer, non-Hodgkin's lymphoma and leukaemia. The major toxicities observed in rodents were on the bone marrow and gastrointestinal tract. Pharmacokinetics were linear with dose and with a bi-exponential decline both in rodents and man. Oral bioavailability in rodents is in the region of 20%. Glucuronidation appears to be the major route of metabolism. Single-agent clinical trials have mainly used a 72 h continuous infusion schedule. Dose-limiting toxicities were diarrhoea and hypotension. Plasma concentrations in excess of those required for in vitro enzyme or cell growth inhibition are achievable. While there has been some evidence of single-agent antitumour activity (partial responses in a patient with renal cancer and another with gastric cancer), ongoing combination studies, especially with paclitaxel, where preclinical synergistic antitumour effects are observed, are promising. Doubt as to whether CDKs are the sole target responsible for the drug's antitumour effects have been raised by preclinical observations of apoptosis of non-cycling cells, effects on endothelial cells and non-CDK proteins, such as aldehyde dehydrogenase and glycogen phosphorylase, potent effects on PTEFb and transcription and its ability to directly interact with DNA.This review focuses on the clinical development of the prototype broad spectrum inhibitor of cyclin-dependent kinases (CDKs), flavopiridol, now undergoing Phase II single-agent trials and Phase I combination trials (with paclitaxel and cisplatin). Preclinically, flavopiridol is a potent inhibitor of CDKs 1, 2 and 4 in cell-free assays (IC(50)in the region of 100 nM) and tumour cell growth in vitro (typical IC(50)in the region of 100 nM). The drug showed in vivo antitumour activity (using iv., ip. or oral dosing) against a variety of human tumour xenografts, especially when administered on a regular daily, rather than weekly, schedule and most notably against prostate carcinoma, head and neck cancer, non-Hodgkin's lymphoma and leukaemia. The major toxicities observed in rodents were on the bone marrow and gastrointestinal tract. Pharmacokinetics were linear with dose and with a bi-exponential decline both in rodents and man. Oral bioavailability in rodents is in the region of 20%. Glucuronidation appears to be the major route of metabolism. Single-agent clinical trials have mainly used a 72 h continuous infusion schedule. Dose-limiting toxicities were diarrhoea and hypotension. Plasma concentrations in excess of those required for in vitro enzyme or cell growth inhibition are achievable. While there has been some evidence of single-agent antitumour activity (partial responses in a patient with renal cancer and another with gastric cancer), ongoing combination studies, especially with paclitaxel, where preclinical synergistic antitumour effects are observed, are promising. Doubt as to whether CDKs are the sole target responsible for the drug's antitumour effects have been raised by preclinical observations of apoptosis of non-cycling cells, effects on endothelial cells and non-CDK proteins, such as aldehyde dehydrogenase and glycogen phosphorylase, potent effects on PTEFb and transcription and its ability to directly interact with DNA. This review focuses on the clinical development of the prototype broad spectrum inhibitor of cyclin-dependent kinases (CDKs), flavopiridol, now undergoing Phase II single-agent trials and Phase I combination trials (with paclitaxel and cisplatin). Preclinically, flavopiridol is a potent inhibitor of CDKs 1, 2 and 4 in cell-free assays (IC 50 in the region of 100 nM) and tumour cell growth in vitro (typical IC 50 in the region of 100 nM). The drug showed in vivo antitumour activity (using iv., ip. or oral dosing) against a variety of human tumour xenografts, especially when administered on a regular daily, rather than weekly, schedule and most notably against prostate carcinoma, head and neck cancer, non-Hodgkin's lymphoma and leukaemia. The major toxicities observed in rodents were on the bone marrow and gastrointestinal tract. Pharmacokinetics were linear with dose and with a bi-exponential decline both in rodents and man. Oral bioavailability in rodents is in the region of 20%. Glucuronidation appears to be the major route of metabolism. Single-agent clinical trials have mainly used a 72 h continuous infusion schedule. Dose-limiting toxicities were diarrhoea and hypotension. Plasma concentrations in excess of those required for in vitro enzyme or cell growth inhibition are achievable. While there has been some evidence of single-agent antitumour activity (partial responses in a patient with renal cancer and another with gastric cancer), ongoing combination studies, especially with paclitaxel, where preclinical synergistic antitumour effects are observed, are promising. Doubt as to whether CDKs are the sole target responsible for the drug's antitumour effects have been raised by preclinical observations of apoptosis of non-cycling cells, effects on endothelial cells and non-CDK proteins, such as aldehyde dehydrogenase and glycogen phosphorylase, potent effects on PTEFb and transcription and its ability to directly interact with DNA. This review focuses on the clinical development of the prototype broad spectrum inhibitor of cyclin-dependent kinases (CDKs), flavopiridol, now undergoing Phase II single-agent trials and Phase I combination trials (with paclitaxel and cisplatin). Preclinically, flavopiridol is a potent inhibitor of CDKs 1, 2 and 4 in cell-free assays (IC50 in the region of 100 nM) and tumour cell growth in vitro (typical IC50 in the region of 100 nM). The drug showed in vivo antitumour activity (using iv., ip. or oral dosing) against a variety of human tumour xenografts, especially when administered on a regular daily, rather than weekly, schedule and most notably against prostate carcinoma, head and neck cancer, non-Hodgkin s lymphoma and leukaemia. The major toxicities observed in rodents were on the bone marrow and gastrointestinal tract. Pharmacokinetics were linear with dose and with a bi-exponential decline both in rodents and man. Oral bioavailability in rodents is in the region of 20%. Glucuronidation appears to be the major route of metabolism. Single-agent clinical trials have mainly used a 72 h continuous infusion schedule. Dose-limiting toxicities were diarrhoea and hypotension. Plasma concentrations in excess of those required for in vitro enzyme or cell growth inhibition are achievable. While there has been some evidence of single-agent antitumour activity (partial responses in a patient with renal cancer and another with gastric cancer), ongoing combination studies, especially with paclitaxel, where preclinical synergistic antitumour effects are observed, are promising. Doubt as to whether CDKs are the sole target responsible for the drug s antitumour effects have been raised by preclinical observations of apoptosis of non-cycling cells, effects on endothelial cells and non-CDK proteins, such as aldehyde dehydrogenase and glycogen phosphorylase, potent effects on PTEFb and transcription and its ability to directly interact with DNA. |
| Author | Kelland, Lloyd R |
| Author_xml | – sequence: 1 givenname: Lloyd R surname: Kelland fullname: Kelland, Lloyd R organization: CRC Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.lloyd@icr.ac.uk |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/11093360$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkc2OFCEUhYkZ4_zoC7gwtXJltVygqC6jCzNxfpJJZqNLQ2jqkmakoQVK028vZc-YOIueFTfk-84NnFNyFGJAQl4DXUAH_XvgneD9UiyGBbAFGyh_Rk6gF6LtZbc8qnMF2pk4Jqc531HK6NDxF-QYgA6cS3pCvl94_StuXXJj9O-assbGupRLY3bGu9COuMUwYijNDxd0xsaFtVu5ElNTYlPvMf2VZtiZD42ZUprpXHSZ8kvy3Gqf8dX9eUa-XXz5en7V3txeXp9_vmlNR3lpJbUS9EpSxkcNnNIeBisNgKaCIvaj7bjkEhEolT1yKcwKjBC9tGIUVvMz8nafu03x54S5qI3LBr3XAeOUVc8EZwD8SZDRGr5ksoJv7sFptcFRbZPb6LRTDz9XgeUeMCnmnNAq4-qbXQwlaecVUDWXpB5KUoMCpuaSqsoeqf_SD0mf9pILNqaN_h2TH1XROx-TTToYlxU_6H_8z1-j9mVtdEJ1F6cUaj2H1v8B2oG6Ow |
| CitedBy_id | crossref_primary_10_1002_med_21510 crossref_primary_10_1074_jbc_M102060200 crossref_primary_10_1038_sj_bjc_6602243 crossref_primary_10_3390_cancers13174389 crossref_primary_10_1002_jps_22568 crossref_primary_10_1002_pbc_24073 crossref_primary_10_1517_13543784_12_4_593 crossref_primary_10_1016_j_nucmedbio_2014_08_008 crossref_primary_10_1007_s13596_013_0124_4 crossref_primary_10_1111_cbdd_13951 crossref_primary_10_1016_j_bmc_2019_115109 crossref_primary_10_1158_1078_0432_CCR_07_1347 crossref_primary_10_1002_ange_200200540 crossref_primary_10_1016_S1471_4892_01_00063_7 crossref_primary_10_1007_s10637_013_0002_4 crossref_primary_10_1016_S1368_7646_02_00141_3 crossref_primary_10_1038_s41598_017_05086_6 crossref_primary_10_1016_j_bmcl_2005_02_076 crossref_primary_10_1093_jnci_93_6_415 crossref_primary_10_1016_j_molcel_2014_04_013 crossref_primary_10_1038_nrd4504 crossref_primary_10_1007_s11095_019_2654_z crossref_primary_10_1016_j_bmc_2006_10_063 crossref_primary_10_1016_j_prp_2023_154693 crossref_primary_10_3816_CLC_2008_n_024 crossref_primary_10_1007_s00894_005_0276_3 crossref_primary_10_1002_anie_200200540 crossref_primary_10_1002_ptr_5669 crossref_primary_10_1006_bcmd_2001_0452 crossref_primary_10_3390_molecules181114070 crossref_primary_10_1074_jbc_M102306200 crossref_primary_10_1007_s00210_024_03599_2 crossref_primary_10_1016_j_bmc_2007_05_022 crossref_primary_10_1016_j_chroma_2013_10_024 crossref_primary_10_1016_j_beha_2010_01_003 crossref_primary_10_1007_s00044_012_0232_6 crossref_primary_10_1016_j_ejmech_2009_04_004 crossref_primary_10_1016_j_biopha_2022_113754 crossref_primary_10_36290_csf_2019_001 crossref_primary_10_1016_j_fitote_2009_08_010 crossref_primary_10_1053_hupa_2003_45 crossref_primary_10_1038_sj_onc_1210123 crossref_primary_10_58920_sciphy01010013 crossref_primary_10_3389_fphar_2017_00109 crossref_primary_10_1002_jhet_2106 crossref_primary_10_1016_j_bcp_2003_07_007 crossref_primary_10_1016_j_canlet_2008_10_045 crossref_primary_10_1016_j_bmcl_2014_08_005 crossref_primary_10_1016_j_imlet_2012_10_004 crossref_primary_10_1186_1471_213X_11_33 crossref_primary_10_1186_1476_4598_5_76 crossref_primary_10_1186_s13045_017_0467_2 crossref_primary_10_1007_s13277_015_3493_0 crossref_primary_10_1016_j_ddmec_2004_10_003 crossref_primary_10_1517_13543784_2011_628985 crossref_primary_10_3389_fonc_2022_828438 crossref_primary_10_1002_med_1021 crossref_primary_10_1006_bcmd_2001_0428 crossref_primary_10_1016_j_ejmech_2013_05_037 crossref_primary_10_1096_fj_04_1646fje crossref_primary_10_3389_fchem_2020_00276 crossref_primary_10_1097_01_cad_0000127332_06439_47 crossref_primary_10_4155_fmc_2016_0013 crossref_primary_10_1016_S1548_5315_11_70246_7 crossref_primary_10_1016_j_bmc_2019_01_027 crossref_primary_10_1016_j_ejmech_2009_11_001 crossref_primary_10_1080_14756366_2020_1740696 crossref_primary_10_1016_j_poly_2021_115638 crossref_primary_10_1007_s00210_024_03341_y crossref_primary_10_1016_j_jconrel_2021_03_042 |
| Cites_doi | 10.1016/0962-8924(96)10034-9 10.1016/S0024-3205(98)00152-0 10.1074/jbc.M005267200 10.1182/blood.V91.2.458 10.1002/(SICI)1097-0215(19980703)77:1<146::AID-IJC22>3.0.CO;2-B 10.1016/S0959-8049(99)00280-4 10.1182/blood.V92.10.3804 10.1006/bbrc.1994.1742 10.1074/jbc.C000446200 10.1038/sj.bjc.6690687 10.1200/JCO.2000.18.2.371 10.1182/blood.V96.2.393 10.1073/pnas.96.8.4325 10.1093/jnci/92.5.376 10.1073/pnas.93.7.2735 10.1016/S0014-5793(99)00773-5 10.1007/s002800050815 10.1074/jbc.M004485200 |
| ContentType | Journal Article |
| Copyright | 2000 Ashley Publications Ltd. ISSN 1354-3784. 2000 |
| Copyright_xml | – notice: 2000 Ashley Publications Ltd. ISSN 1354-3784. 2000 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TM 7X8 |
| DOI | 10.1517/13543784.9.12.2903 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Nucleic Acids Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Nucleic Acids Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Nucleic Acids Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1744-7658 |
| EndPage | 2911 |
| ExternalDocumentID | 11093360 10_1517_13543784_9_12_2903 11199698 |
| Genre | Research Article Journal Article Review |
| GroupedDBID | --- 00X 03L 0BK 0R~ 0VX 29G 4.4 53G 5GY AAMIU AAOUU AAPWH AAPXX ABBAB ABBKH ABEIZ ABJYH ABLKL ACFUF ACGFO ACGFS ADCVX ADFCX ADTOD AECIN AENEX AEOZL AEYQI AGDLA AGMLL AIJEM AIRBT AIYSM AKBVH ALIIL ALMA_UNASSIGNED_HOLDINGS ALQZU BABNJ BLEHA CAZVN CCCUG CS3 DASJU DAWQK DKSSO DU5 EBS EJD F5P FERIO H13 HZ~ KRBQP KSSTO KWAYT KYCEM M44 M4Z O9- P2P RNANH TAVEC TFDNU TFL TFW TZHSB V1S ~1N ABJNI ABLIJ ABXYU ACIEZ AFRVT AGMHR AQTUD TASJS TBQAZ TDBHL TERGH TUROJ AAYXX ABECT ADRBQ AEIZR AFFVI AGVBG AIHVM AILGL CITATION EMOBN IFJUI LJTGL LSO S70 ABVAX CGR CUY CVF ECM EIF NPM 7TM 7X8 |
| ID | FETCH-LOGICAL-c503t-60f61ab6023da1300719f6c11a040ee7df53636ee10067e364cb1c4476f4d4fa3 |
| IEDL.DBID | TFW |
| ISICitedReferencesCount | 119 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000166080800010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1354-3784 |
| IngestDate | Thu Oct 02 06:02:31 EDT 2025 Fri Sep 05 09:34:20 EDT 2025 Thu Jan 02 21:49:17 EST 2025 Tue Nov 18 22:25:16 EST 2025 Sat Nov 29 03:54:20 EST 2025 Mon Oct 20 23:45:58 EDT 2025 Wed Jun 21 08:14:37 EDT 2023 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c503t-60f61ab6023da1300719f6c11a040ee7df53636ee10067e364cb1c4476f4d4fa3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Review-3 |
| PMID | 11093360 |
| PQID | 20364826 |
| PQPubID | 23462 |
| PageCount | 9 |
| ParticipantIDs | crossref_citationtrail_10_1517_13543784_9_12_2903 crossref_primary_10_1517_13543784_9_12_2903 proquest_miscellaneous_20364826 informaworld_taylorfrancis_310_1517_13543784_9_12_2903 proquest_miscellaneous_72432113 informahealthcare_journals_10_1517_13543784_9_12_2903 pubmed_primary_11093360 |
| PublicationCentury | 2000 |
| PublicationDate | 2000-12-01 |
| PublicationDateYYYYMMDD | 2000-12-01 |
| PublicationDate_xml | – month: 12 year: 2000 text: 2000-12-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Expert opinion on investigational drugs |
| PublicationTitleAlternate | Expert Opin Investig Drugs |
| PublicationYear | 2000 |
| Publisher | Ashley Publications Ltd Taylor & Francis |
| Publisher_xml | – name: Ashley Publications Ltd – name: Taylor & Francis |
| References | SEDLACEK HH (CIT0006) 1996; 9 SCHWARTZ GK (CIT0054) 1997; 3 SCHRUMP DS (CIT0024) 1998; 4 SCHWARTZ GK (CIT0055) 1999 CIT0031 CIT0012 CIT0034 MOTVVANI M (CIT0052) 1999; 5 DREES M (CIT0010) 1997; 3 SHAPIRO GI (CIT0025) 1999; 5 PATEL V (CIT0042) 1998; 102 BIBLE KC (CIT0038) 2000; 6 CARLSON BA (CIT0014) 1996; 37 CIT0035 CARLSON B (CIT0017) 1999; 59 KITADA S (CIT0028) 2000; 96 CIT0015 CIT0018 WERNER JL (CIT0058) 1998; 17 SHAPIRO G (CIT0057) 1999; 18 BYRD JC (CIT0022) 1998; 92 CIT0061 FRY DW (CIT0064) 2000; 2 SMITH V (CIT0039) 2000; 41 CIT0063 CIT0040 CIT0043 STADLER WM (CIT0059) 2000; 18 SENDEROWICZ AM (CIT0045) 1998; 16 PARKER BW (CIT0023) 1998; 91 ARGUELLO F (CIT0020) 1998; 91 BIBLE KC (CIT0036) 2000; 60 BENNET P (CIT0056) 1999; 18 KELLAND LR (CIT0009) 1999; 40 INNOCENTI F (CIT0044) 2000; 6 THOMAS J (CIT0048) 1997; 38 BIBLE KC (CIT0050) 1997; 57 CARLSON BA (CIT0013) 1996; 56 BIBLE KC (CIT0029) 1996; 56 LI Y (CIT0026) 2000; 5 MOTVVANI M (CIT0033) 2000; 6 CIT0047 CIT0005 CIT0027 CZECH J (CIT0041) 1995; 6 SENDEROWICZ AM (CIT0049) 2000; 19 CIT0004 |
| References_xml | – volume: 17 start-page: 896 year: 1998 ident: CIT0058 publication-title: Proc. ASCO – ident: CIT0063 doi: 10.1016/0962-8924(96)10034-9 – ident: CIT0043 doi: 10.1016/S0024-3205(98)00152-0 – ident: CIT0027 doi: 10.1074/jbc.M005267200 – volume: 6 start-page: 924 year: 2000 ident: CIT0033 publication-title: Clin. Cancer Res. – volume: 91 start-page: 458 year: 1998 ident: CIT0023 publication-title: Blood doi: 10.1182/blood.V91.2.458 – ident: CIT0031 doi: 10.1002/(SICI)1097-0215(19980703)77:1<146::AID-IJC22>3.0.CO;2-B – volume: 5 start-page: 1876 year: 1999 ident: CIT0052 publication-title: an. Cancer Res. – volume: 18 start-page: 1065 year: 1999 ident: CIT0056 publication-title: Proc. ASCO – ident: CIT0004 doi: 10.1016/S0959-8049(99)00280-4 – volume: 91 start-page: 2482 year: 1998 ident: CIT0020 publication-title: Blood – volume: 60 start-page: 2419 year: 2000 ident: CIT0036 publication-title: Cancer Res. – volume: 2 start-page: 40 year: 2000 ident: CIT0064 publication-title: Curr. Opin. Oncol. Endocr. Metab. Invest. Drugs – volume: 92 start-page: 3804 year: 1998 ident: CIT0022 publication-title: Blood doi: 10.1182/blood.V92.10.3804 – volume: 5 start-page: 2925 year: 1999 ident: CIT0025 publication-title: Clin. Cancer Res. – volume: 6 start-page: 3400 year: 2000 ident: CIT0044 publication-title: Clin. Cancer Res. – ident: CIT0012 doi: 10.1006/bbrc.1994.1742 – ident: CIT0018 doi: 10.1074/jbc.C000446200 – ident: CIT0040 doi: 10.1038/sj.bjc.6690687 – volume: 59 start-page: 4634 year: 1999 ident: CIT0017 publication-title: Cancer Res – volume: 19 start-page: 796 year: 2000 ident: CIT0049 publication-title: Proc. ASCO – volume: 57 start-page: 3375 year: 1997 ident: CIT0050 publication-title: Cancer Res – volume: 18 start-page: 371 year: 2000 ident: CIT0059 publication-title: J. Clin. Oncol doi: 10.1200/JCO.2000.18.2.371 – volume: 4 start-page: 2885 year: 1998 ident: CIT0024 publication-title: Clin. Cancer Res. – volume: 6 start-page: 661 year: 2000 ident: CIT0038 publication-title: Clin. Cancer Res. – volume: 96 start-page: 393 year: 2000 ident: CIT0028 publication-title: Blood doi: 10.1182/blood.V96.2.393 – volume: 3 start-page: 1467 year: 1997 ident: CIT0054 publication-title: Clin. Cancer Res. – ident: CIT0061 doi: 10.1073/pnas.96.8.4325 – ident: CIT0005 doi: 10.1093/jnci/92.5.376 – volume: 18 start-page: 2013 year: 1999 ident: CIT0057 publication-title: Proc. ASCO – volume: 9 start-page: 1143 year: 1996 ident: CIT0006 publication-title: Int. J. Oncol – ident: CIT0015 doi: 10.1073/pnas.93.7.2735 – volume: 102 start-page: 1674 year: 1998 ident: CIT0042 publication-title: et al.:Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. Clin. Invest. – volume: 37 start-page: 424 year: 1996 ident: CIT0014 publication-title: Proc. AACR – volume: 5 start-page: 223 year: 2000 ident: CIT0026 publication-title: Clin. Cancer Res. – volume: 56 start-page: 2973 year: 1996 ident: CIT0013 publication-title: Cancer Res – volume: 41 start-page: 207 year: 2000 ident: CIT0039 publication-title: Proc. AACR – volume: 3 start-page: 273 year: 1997 ident: CIT0010 publication-title: Clin. Cancer Res. – volume: 56 start-page: 4856 year: 1996 ident: CIT0029 publication-title: Cancer Res – ident: CIT0034 doi: 10.1016/S0014-5793(99)00773-5 – start-page: 26 year: 1999 ident: CIT0055 publication-title: Proc. AACR/NCl/EORTC – ident: CIT0047 doi: 10.1007/s002800050815 – ident: CIT0035 doi: 10.1074/jbc.M004485200 – volume: 16 start-page: 2986 year: 1998 ident: CIT0045 publication-title: STINSON SF etal.: Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. °rico/. – volume: 6 start-page: 31 year: 1995 ident: CIT0041 publication-title: Int. J Oncol. – volume: 40 start-page: 125 year: 1999 ident: CIT0009 publication-title: Proc. AACR – volume: 38 start-page: 222 year: 1997 ident: CIT0048 publication-title: Proc. AACR |
| SSID | ssj0020953 |
| Score | 1.9651964 |
| SecondaryResourceType | review_article |
| Snippet | This review focuses on the clinical development of the prototype broad spectrum inhibitor of cyclin-dependent kinases (CDKs), flavopiridol, now undergoing... |
| SourceID | proquest pubmed crossref informaworld informahealthcare |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2903 |
| SubjectTerms | Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use cancer Clinical Trials as Topic cyclin-dependent kinase Cyclin-Dependent Kinases - antagonists & inhibitors Flavonoids - pharmacology Flavonoids - therapeutic use flavopiridol Humans inhibitor Neoplasms - drug therapy Piperidines - pharmacology Piperidines - therapeutic use |
| Title | Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status |
| URI | https://www.tandfonline.com/doi/abs/10.1517/13543784.9.12.2903 https://www.ncbi.nlm.nih.gov/pubmed/11093360 https://www.proquest.com/docview/20364826 https://www.proquest.com/docview/72432113 |
| Volume | 9 |
| WOSCitedRecordID | wos000166080800010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAWR databaseName: Taylor and Francis Online Journals customDbUrl: eissn: 1744-7658 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0020953 issn: 1354-3784 databaseCode: TFW dateStart: 19940101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LbxMxELag6oELlPIqj-ID6oUsxLHXXnNDqBEHVOUQRC7I8vqhroh2q91Npfx7PPYm4dUc6N1jrb0znvnsmW8QekMJ0wEl24yUXGaMllCsbGjmdKGFNFYWLnYt-SIuLorFQs6GC7duSKsEDO0TUUQ8q8G4dZk6kOREvCc0Z1QU7J2Em7yJjGSfIayHjL759NsWbwGVWsRbOctg_FAz8-8pfvNLRwNr6eU2B-sPJtOb49Hol6YPbruiI3R_iEjxx6RCD9EdVx-js1mitF6P8HxXodWN8Bme7ciu14_Q9-lSXzdXVVvZZjnCIZzEvgoRJTZrKLrMNk12e_yjqoPHxFV9WZXhGGlx32AgBG2jUKrQ_IBN4ovCUOi06h6jr9Pz-afP2dCyITP5mPYZH3tOdMlDJGA1vJQJIj03hOhwWDgnrM8pp9w5Am7SUc5MSQxjgntmmdf0CTqom9o9Q9gIA_x3NnfUM0FtIbUlwpuiDEGelOIEkc0PU2bgM4e2GksFuCbsqtrsqpKKTBTs6gl6u5W5Smwee0fnf-mBGky82yvHf9UV1ce7F58apSi6T_D1RqtUsHJ4utG1a1adis_FAQnePEJMGA1gPszxNKnjboHAGEb5-Pn_ftYLdC8SEMQknpfooG9X7hU6NNd91bWn6K5YFKfR8n4CxEwpDw |
| linkProvider | Taylor & Francis |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Nb9MwFLfQQIILjO8BYz6gXWigrh075jZNq4YoVQ9F7IIsxx9aRJVMSTqp_z1-TtrytR7g7mfFznv2-9l-vx9CbyhhOqBkm5Ccy4TRHIqVDU2czrSQxsrMRdWSiZhOs4sLOet1Tpv-WSVgaN8RRcS1GoIbDqM7uR4i3hOaMioy9k7CUd5IAtvnbZCmA_Q1H3_dIC4gU4uIK2UJGPRVM3_v45edab_nLb3cvML6jcv05ow07kzjB_89pn10v09K8UnnRQ_RLVc-QsezjtV6NcDzbZFWM8DHeLblu149Rt_GC31dXRV1YavFAIeMEvsiJJXYrKDuMlnr7Lb4e1GGTRMX5WWRh5Wkxm2FgRO0jkZdkeYHbDrKKAy1TsvmCfoyPpufnie9akNi0iFtEz70nOich2TAargsE0R6bgjRYb1wTlifUk65cwR2Skc5MzkxjAnumWVe06dor6xK9xxhIwxQ4NnUUc8EtZnUlghvsjzkeVKKA0TWf0yZntIclDUWCqBNmFW1nlUlFRkpmNUD9HZjc9UReuxsnf7hCKqP8manHf_ZWVQbj198p5Wi6C7Do7VbqRDocHujS1ctGxVvjAMYvLmFGDEa8Hzo41nnj9sBAmkY5cMX__pZR-ju-fzzRE0-Tj-9RPciH0F80_MK7bX10h2iO-a6LZr6dQzAH2JDLEo |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELbQghAXWN7La31Ae6Fh69qxY24IiECsqh6K2AuyHD-0EVVSJelK_fd4nLTltT3A3WPFzoxnPnvmG4ReUsJ0QMk2IQWXCaMFFCsbmjidaSGNlZmLXUvOxHSanZ_L2XDh1g5plYChfU8UEc9qMO6l9X23HiJOCU0ZFRl7LeEmbyKB7PN6iJtT0Op5_nULuIBLLQKulCUgMBTN_H2OXxzT4UBberFNwvqNyvTqgDQ6pvzO_y7pEN0eQlL8ttehu-iaq-6hk1nPab0e4fmuRKsd4RM827Fdr--jb_lCX9bLsiltvRjhEE9iX4aQEps1VF0mmy67Hf5eVsFl4rK6KItwjjS4qzEwgjZRqC_RfINNTxiFodJp1T5AX_IP83cfk6FnQ2LSMe0SPvac6IKHUMBqeCoTRHpuCNHhtHBOWJ9STrlzBPyko5yZghjGBPfMMq_pQ3RQ1ZV7jLARBgjwbOqoZ4LaTGpLhDdZEaI8KcURIpsfpsxAaA59NRYKgE3YVbXZVSUVmSjY1SP0aiuz7Ok89o5O_9ADNdh4u1eO_6wrqouXL77vlKLoPsHjjVapYObwdqMrV69aFd-LAxS8eoSYMBrQfJjjUa-OuwUCZRjl4yf_-lnH6Obsfa7OPk0_P0W3IhlBTOh5hg66ZuWeoxvmsivb5kU0vx-1Kyr8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Flavopiridol%2C+the+first+cyclin-dependent+kinase+inhibitor+to+enter+the+clinic%3A+current+status&rft.jtitle=Expert+opinion+on+investigational+drugs&rft.au=Kelland%2C+L+R&rft.date=2000-12-01&rft.issn=1354-3784&rft.volume=9&rft.issue=12&rft.spage=2903&rft.epage=2911&rft_id=info:doi/10.1517%2F13543784.9.12.2903&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1354-3784&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1354-3784&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1354-3784&client=summon |